A phase 1B study of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies

niversity Medical Center Erasmus Medical Center Rotterdam The Netherlands0 sites82 target enrollmentTBD

Conditionschildren, cancer, pediatric malignancies, ALK positive tumors, ROS1 positive tumors, MET positive tumorskinderen, kanker, pediatrische maligniteiten, tumoren positief voor ALK, ROS1, MET afwijkingen

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: children, cancer, pediatric malignancies, ALK positive tumors, ROS1 positive tumors, MET positive tumorskinderen, kanker, pediatrische maligniteiten, tumoren positief voor ALK, ROS1, MET afwijkingen
Sponsor: niversity Medical Center Erasmus Medical Center Rotterdam The Netherlands
Enrollment: 82
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

niversity Medical Center Erasmus Medical Center Rotterdam The Netherlands

Eligibility Criteria

Inclusion Criteria

•Inclusion criteria stratum 1
•Histologically or cytologically confirmed diagnosis of ALCL

Exclusion Criteria

•Other serious illnesses or medical conditions

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting

Phase 1

Study into the safety and activity of the drug Crizotinib for children with malignant tumors

EUCTR2015-005437-53-NLErasmus Medical Center71

Active, not recruiting

Phase 1

Study evaluating the safety and activity of the drug Crizotinib for children with malignant tumorsChildren and young adults with malignancies carrying a genetic alteration of ALK, MET or ROS1 with no better treatment options according to the current (inter)national guidelinesTherapeutic area: Diseases [C] - Cancer [C04]

EUCTR2015-005437-53-DEErasmus Medical Center82

Active, not recruiting

Phase 1

Study into the safety and activity of the drug Crizotinib for children with malignant tumors

EUCTR2015-005437-53-DKErasmus Medical Center71

Recruiting

Phase 2

A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies;Study ITCC 053cancermalignancies10027655

NL-OMON54812Erasmus MC, Universitair Medisch Centrum Rotterdam20

Active, not recruiting

Phase 1

Study into the safety and activity of the drug Crizotinib for children with malignant tumorsMalignancies carrying a genetic alteration of ALK, MET or ROS1Therapeutic area: Diseases [C] - Cancer [C04]

EUCTR2015-005437-53-IEErasmus Medical Center82